Morphic Announces Participation in 2023 Wells Fargo Healthcare Conference
August 29, 2023 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Present at the Jefferies Global Healthcare Conference
June 06, 2023 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Therapeutic Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 05, 2023 10:30 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (“Morphic”), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious chronic...
Morphic Therapeutic Announces Proposed Public Offering
May 02, 2023 16:02 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Morphic Holding, Inc. (Nasdaq: MORF), a biopharmaceutical company developing a portfolio of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Second Quarter 2020 Financial Results
August 10, 2020 07:00 ET
|
Morphic Therapeutic
Company’s first IND accepted by FDA for MORF-057 in IBDPhase 1 study expected to begin in third-quarter 2020Positive data presented at DDW 2020 further support MORF-057 preclinical profile WALTHAM,...
Morphic to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference
June 18, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic to Present at the Jefferies Virtual Healthcare Conference
May 27, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., May 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic Announces Corporate Highlights and First Quarter 2020 Financial Results
May 06, 2020 16:05 ET
|
Morphic Therapeutic
Data presented at ECCO Congress support MORF-057 in IBD; IND on track for mid-year Recent executive appointments of Peter Linde, M.D., as CMO and Marc Schegerin, M.D., as CFO and COO ...
Morphic Therapeutic to Present at the BofA Securities 2020 Health Care Conference
April 29, 2020 16:15 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral therapies targeting integrins for the treatment...
Morphic Announces Appointment of Marc Schegerin, M.D., as Chief Financial Officer and Chief Operating Officer
April 07, 2020 08:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., April 07, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...